A shift towards advanced robotic mobility is underway as Wandercraft, a Paris-based company, announces its $75 million Series D funding round. Known for developing self-balancing robotic systems, Wandercraft aims to broaden the application of its technologies across clinical, consumer, and industrial domains. This substantial investment will enable the firm to accelerate product development and expand its market reach. Investors include notable names such as Renault Group and Bpifrance, which signifies trust in Wandercraft’s innovative solutions in the realm of mobility.
In earlier stages, Wandercraft gained attention for its AI-driven exoskeleton technology aimed at improving mobility for those with disabilities. Significant funding rounds, like the Series C of $45 million, allowed the company to venture into the U.S. market and establish pivotal partnerships. The continuous support from existing and new investors showcases the company’s steady growth and the increasing demand for robotic mobility solutions. Wandercraft’s consistent technological advancements set it apart in a competitive field, attracting diverse investment sources.
How is Wandercraft Redefining Mobility?
Wandercraft’s mission revolves around developing self-balancing robotic systems, such as the Atalante X exoskeleton. This device is designed to aid individuals with disabilities in rehabilitation settings, proving instrumental in helping users achieve mobility milestones globally. The technology underpinning these systems is backed by a decade’s worth of data collection and sophisticated neural networks, enabling precise and adaptable support tailored to individual needs.
What Does the Future Hold for Wandercraft?
With the new funds, Wandercraft intends to introduce an exoskeleton called Eve, focusing on personal use to assist wheelchair users in everyday settings. The company is also exploring the industrial sector with the Calvin line of humanoid robots, highlighting a commitment to enhancing mobility in various environments. By prioritizing innovation, Wandercraft is poised to reshape how robotic systems integrate into daily life and work environments.
A strategic partnership with Renault Group adds another dimension to Wandercraft’s growth strategy. This collaboration will leverage Renault’s industrial expertise, enabling mass production and commercialization of Wandercraft’s robotic solutions. Renault’s involvement further validates the potential applications of these technologies in commercial settings, broadening Wandercraft’s market reach.
Paul-François Fournier from Bpifrance expressed enthusiasm for continued support.
“We are delighted to renew our support for Wandercraft. This D Series will enable the company to accelerate the industrial deployment of its unique robotics technology,” he stated.
Wandercraft’s initiatives align with delivering accessible mobility solutions. The company has made strides in gaining regulatory clearance, like the FDA approval of its Atalante X for stroke rehabilitation, exemplifying the technological adeptness in the medical field. With over 100 rehabilitation centers using Wandercraft’s systems, the company continues to play a vital role in improving patient outcomes globally.
The culmination of Wandercraft’s efforts is evident through real-world feedback, with users achieving improved walking speeds, balance, and postural control. By investing in widespread clinical trials, the company demonstrates a commitment to evidence-based product development. Further expansion in the U.S., such as establishing a dedicated center in New York, underscores its intent to bridge the gap between cutting-edge technology and everyday application.
